Source-grounded facts extracted from Medpace Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Brad W. Hansman was appointed as Executive Vice President, Operations at Medpace Holdings, Inc..
“Effective June 1, 2026, Medpace Holdings, Inc. (the “ Company ”) appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations.”
Medpace Holdings, Inc.: Amended Second Amended and Restated Bylaws to remove limitation on stockholders calling special meetings, allow owners of 25% voting power to call a special meeting, and implement conforming changes.
“the Board approved amendments to the Second Amended and Restated Bylaws of the Company to remove the limitation on stockholders calling special meetings of stockholders, to provide one or more stockholders as a group owning at least 25% of the voting power of the Company’s outstanding shares the right to call a special meeting, and to implement other conforming and clarifying changes”
Medpace Holdings, Inc.: Removed supermajority voting requirements and limitation on stockholders calling special meetings via amendments to the Restated Certificate of Incorporation (effective 2026-05-18).
“(i) to remove supermajority voting requirements and (ii) to remove the limitation on stockholders calling special meetings of stockholders. The Amendments became effective immediately upon the filing of a certificate of amendment setting forth the same with the Secretary of State of the State of Delaware on May 18, 2026.”
Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2026.
“Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. The full text of the press release was posted on the Company’s internet website and is furnished as Exhibit 99.1 hereto and incorporated herein by reference.”
Dani S. Zander was elected as Director at Medpace Holdings, Inc..
“The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024”
Ashley M. Keating resigned as Director at Medpace Holdings, Inc..
“On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.”
Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2024.
“On April 22, 2024, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024.”
Medpace Holdings, Inc. amended Amendment No. 6 to Loan Documents with PNC Bank, National Association valued at up to $10 million (effective 2024-03-28).
“Medpace Holdings, Inc., a Delaware corporation (the "Company"), through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 6 to Loan Documents (“Amendment No. 6”) with PNC Bank, National Association”
Medpace Holdings, Inc. reported financial results for the three and twelve months ended December 31, 2023.
“On February 12, 2024, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.”
Medpace Holdings, Inc. reported financial results for three and nine months ended September 30, 2023.
“On October 23, 2023, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2023.”
Medpace Holdings, Inc. reported financial results for the three and six months ended June 30, 2023.
“On July 24, 2023, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.”
Medpace Holdings, Inc. shareholders approved Advisory Vote on the Compensation of our Named Executive Officers at the 2023-05-19 meeting.
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07. Submission of Matters to a Vote of Security Holders. (a) On May 19, 2023, Medpace Holdings, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders. (b) Stockholders voted on the matters set forth below. Proposal 1 - Election of Directors The following nominees were elected to the Company’s Board of Directors to serve as Class I Directors until the Company’s 2026 Annual Meeting of Stockholders based upon the following votes: Votes For Votes Withheld Broker Non-Votes Brian T. Carley 15,744,076 12,066,720 1,172,784 Femida H. Gwadry-Sridhar 27,027,873 782,923 1,172,784 Robert O. Kraft 15,166,913 12,643,883 1,172,784 Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Deloitte & Touche LLP as the Company’s i”
Medpace Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-19 meeting.
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07. Submission of Matters to a Vote of Security Holders. (a) On May 19, 2023, Medpace Holdings, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders. (b) Stockholders voted on the matters set forth below. Proposal 1 - Election of Directors The following nominees were elected to the Company’s Board of Directors to serve as Class I Directors until the Company’s 2026 Annual Meeting of Stockholders based upon the following votes: Votes For Votes Withheld Broker Non-Votes Brian T. Carley 15,744,076 12,066,720 1,172,784 Femida H. Gwadry-Sridhar 27,027,873 782,923 1,172,784 Robert O. Kraft 15,166,913 12,643,883 1,172,784 Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Deloitte & Touche LLP as the Company’s i”
Medpace Holdings, Inc. shareholders approved Election of Directors at the 2023-05-19 meeting.
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.07. Submission of Matters to a Vote of Security Holders. (a) On May 19, 2023, Medpace Holdings, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders. (b) Stockholders voted on the matters set forth below. Proposal 1 - Election of Directors The following nominees were elected to the Company’s Board of Directors to serve as Class I Directors until the Company’s 2026 Annual Meeting of Stockholders based upon the following votes: Votes For Votes Withheld Broker Non-Votes Brian T. Carley 15,744,076 12,066,720 1,172,784 Femida H. Gwadry-Sridhar 27,027,873 782,923 1,172,784 Robert O. Kraft 15,166,913 12,643,883 1,172,784 Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of Deloitte & Touche LLP as the Company’s i”
Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2023.
“On April 24, 2023, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023.”
Medpace Holdings, Inc. amended Amendment No. 5 to Loan Documents with PNC Bank, National Association valued at up to $150 million (effective 2023-03-31).
“On March 31, 2023, Medpace Holdings, Inc., a Delaware corporation (the "Company"), through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 5 to Loan Documents (“Amendment No. 5”) with PNC Bank, National Association in connection with the Company’s unsecured credit facility (the “Loan Documents”).”
Medpace Holdings, Inc. reported financial results for three and twelve months ended December 31, 2022.
“issued a press release announcing its financial results for the three and twelve months ended December 31, 2022”
Femida H. Gwadry-Sridhar was elected as Class I Director at Medpace Holdings, Inc..
“unanimously approved that Dr. Femida H. Gwadry-Sridhar be elected to fill the Class I director vacancy on the Board of the Company, effective January 16, 2023”
Thomas C. King resigned as member of the Board of Directors at Medpace Holdings, Inc..
“On December 31, 2022, Thomas C. King, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of his resignation from the Board, effective as of December 31, 2022.”
Kevin M. Brady was appointed as Chief Financial Officer at Medpace Holdings, Inc..
“Kevin M. Brady to the position of Chief Financial Officer”
Jesse J. Geiger was appointed as President at Medpace Holdings, Inc..
“appointments of Jesse J. Geiger to the position of President”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.